Related references
Note: Only part of the references are listed.Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2012)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Adherence to Adalimumab Therapy in Crohn's Disease: A French Multicenter Experience
Vincent Billioud et al.
INFLAMMATORY BOWEL DISEASES (2011)
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
A. W. G. Waugh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders
D. Laharie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report
David Yiu-Kuen But et al.
VACCINE (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Two-year follow-up of anti-transglutaminase autoantibodies among celiac children on gluten-free diet:: Comparison of IgG and IgA
Ainhoa Martin-Pagola et al.
AUTOIMMUNITY (2007)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Persistence of neutralizing antibodies after discontinuation of IFN beta therapy in patients with relapsing-remitting multiple sclerosis
B Petersen et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Antibody levels in adult patients with coeliac disease during gluten-free diet:: a rapid initial decrease of clinical importance
G Midhagen et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Pneumococcal vaccination and revaccination of older adults
AS Artz et al.
CLINICAL MICROBIOLOGY REVIEWS (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
